Literature DB >> 20181803

Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease.

Betti Schaefer1, Katja Schlosser, Elke Wühl, Petra Schall, Günter Klaus, Franz Schaefer, Claus Peter Schmitt.   

Abstract

BACKGROUND: Hyperparathyroidism (HPT) is an essential contributor to bone disease and cardiovascular calcifications in children with chronic kidney disease (CKD). Pharmacological and dietary interventions are of limited efficacy; calcimimetics are not yet recommended in children. Parathyroidectomy (PTX) is ultimately performed if HPT becomes refractory to conservative measures; the long-term results and the impact of subsequent kidney transplantation (NTX), however, have not yet been evaluated.
METHODS: We analyzed the postsurgical course of 18 paediatric CKD patients with refractory HPT who underwent PTX and autotransplantation of tissue fragments. PTX was successful in all but one patient with an ectopic fifth gland; median follow-up time was 8.3 (range 2.8-19) years.
RESULTS: Parathyroid hormone (PTH) dropped within 1 year after PTX from 1030 +/- 108 to 98 +/- 18 pg/ml, Ca*P from 59.5 +/- 3 to 49 +/- 2 mg(2)/dl(2). Oral calcium supply transiently increased from 18.7 +/- 4.2 to 24.1 +/- 4.8 mg/kg/day within the first 6 months (all P < 0.05). Haemoglobin increased from 10.7 +/- 0.4 to 11.5 +/- 0.3 g/dl (P < 0.01), despite similar erythropoietin dose and ferritin levels. In patients on long-term dialysis, Ca*P increased again after 18 months; three patients required a second PTX after 3.8, 12 and 12.3 years. Twelve patients underwent NTX 1.8 (0.3-3.8) years after PTX, which decreased mean PTH and Ca*P into the target range throughout the entire post-NTX observation period. Postoperative complications included one transient recurrent nerve palsy, one hypocalcaemic seizure and a case of haemopericardium. At present, no patient has clinical signs of bone disease.
CONCLUSIONS: PTX accomplishes long-term control of HPT and calcium-phosphate metabolism in children with CKD and following PTX and may thus mitigate uraemic bone and cardiovascular disease. This has to be taken into account if alternative long-term therapy with calcimimetics (with as yet unknown effects on longitudinal growth and pubertal development) is considered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181803     DOI: 10.1093/ndt/gfq074

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

Review 1.  Osteocalcin: a pivotal mediator or an innocent bystander in energy metabolism?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2010-12-03       Impact factor: 5.992

Review 2.  Systematic review of oral manifestations related to hyperparathyroidism.

Authors:  Benjamin Palla; Egon Burian; Riham Fliefel; Sven Otto
Journal:  Clin Oral Investig       Date:  2017-06-14       Impact factor: 3.573

Review 3.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

Review 4.  Cardiovascular complications in children with chronic kidney disease.

Authors:  Rukshana Shroff; Donald J Weaver; Mark M Mitsnefes
Journal:  Nat Rev Nephrol       Date:  2011-09-13       Impact factor: 28.314

5.  Cinacalcet ameliorates aortic calcification in uremic rats via suppression of endothelial-to-mesenchymal transition.

Authors:  Min Wu; Ri-Ning Tang; Hong Liu; Ming-Ming Pan; Bi-Cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2016-09-05       Impact factor: 6.150

6.  Parathyroid hormone levels in long-term renal transplant children and adolescents.

Authors:  Isabella Guzzo; Giacomo Di Zazzo; Chiara Laurenzi; Lucilla Ravà; Germana Giannone; Stefano Picca; Luca Dello Strologo
Journal:  Pediatr Nephrol       Date:  2011-05-10       Impact factor: 3.714

Review 7.  Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation?

Authors:  Rukshana Shroff; Catherine Quinlan; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2010-11-16       Impact factor: 3.714

8.  Molecular regulation of phosphate metabolism by fibroblast growth factor-23-klotho system.

Authors:  Chung-Yi Cheng; Makoto Kuro-o; Mohammed S Razzaque
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

9.  Severe secondary hyperparathyroidism and panoramic radiography parameters.

Authors:  João César Guimarães Henriques; Julio Cezar de Melo Castilho; Reinhilde Jacobs; José Benedito Oliveira Amorim; Rafaela Rangel Rosa; Caio Vinícius Bardi Matai
Journal:  Clin Oral Investig       Date:  2013-07-12       Impact factor: 3.573

10.  Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.

Authors:  Winnie Sohn; Isidro B Salusky; Claus Peter Schmitt; Christina Taylan; Johan Vande Walle; Jude Ngang; Lucy Yan; Mark Kroenke; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2020-07-09       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.